Sign in
CompletedNo phase

The Effect of Methylphenidate Treatment on Oxidative Stress Levels in Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)

Key facts

Who runs it
Saglik Bilimleri Universitesi
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
39 people enrolled
Started
26 Jun 2024
Ended
6 Jan 2025
Type of study
Observational
Treatments tested
  • This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study.
Record updated
8 June 2025

Who can take part

Age
6 years to 11 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • - A diagnosis of "Attention Deficit Hyperactivity Disorder" according to DSM-5 TR, and the initiation or planned initiation of methylphenidate treatment as part of routine care
  • Being between the ages of 6 and 11
  • Providing consent to participate in the study after being informed about the study

Who cannot take part

  • Previous use of psychiatric medication
  • Use of regular medication
  • - Presence of a psychiatric disorder diagnosis other than "Attention Deficit Hyperactivity Disorder."
  • The diagnosis of "Attention Deficit Hyperactivity Disorder" has been made, but methylphenidate treatment has not been planned
  • Presence of organic brain damage, mental retardation, autism spectrum disorder, neurological diseases, or any physical illness affecting neurocognitive functions
  • A history of alcohol and/or psychoactive substance use
  • Presence of ongoing active infection, allergic diseases, or chronic illness
  • Presence of a chronic illness
  • Being under the age of 6 or over the age of 11

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to investigate the effect of methylphenidate treatment on oxidative stress by measuring the levels of Total Oxidant Status (TOS), Total Antioxidant Status (TAS), Oxidative Stress Index (OSI=TOS/TAS), Malondialdehyde (MDA), Oxidized LDL (Ox-LDL), and Superoxide Dismutase (SOD) in serum samples of patients diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who have either started or are planned to start methylphenidate treatment. The measurements will be taken at baseline (0 months, before treatment initiation) and at the 3rd month (after treatment has begun) to assess the effect of methylphenidate on oxidative stress. Patients who were already planned to begin methylphenidate treatment will be invited to participate in this study. Since this is not an interventional study, no additional treatments will be administered or altered beyond the treatment the patient is already required to receive.

The group in the trial

  • Patient group

    Patient group with attention deficit and hyperactivity disorder. The group planned to start methylphenidate treatment independent of the study

    Treatment: This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
8 June 2025